Oxidative stress and dysfunctional NRF2 underlie pachyonychia congenita phenotypes

Journal of Clinical Investigation

Volumn 126, Issue 6, 2016, Pages 2356-2366

  Kerns, Michelle L ^a   Hakim, Jill M C ^a   Lu, Rosemary G ^a   Guo, Yajuan ^a   Berroth, Andreas ^b   Kaspar, Roger L ^c   Coulombe, Pierre A ^d  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TransDerm Inc   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE; HEME OXYGENASE 1; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MESSENGER RNA; PROTEIN KINASE C DELTA; PROTEIN P21; RECEPTOR FOR ACTIVATED C KINASE 1; TRANSCRIPTION FACTOR NRF2; CYTOKERATIN 16; ISOTHIOCYANIC ACID DERIVATIVE; KRT16 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; NFE2L2 PROTEIN, MOUSE; SULFORAFAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONGENITAL PACHYONYCHIA; CONTROLLED STUDY; GENE EXPRESSION; GLUTATHIONE METABOLISM; KERATINOCYTE; MALE; MOUSE; NONHUMAN; NULL ALLELE; OXIDATIVE STRESS; PALMOPLANTAR KERATODERMA; PAW TISSUE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SKIN BIOPSY; SKIN DEFECT; UPREGULATION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CHEMISTRY; DEFICIENCY; DISEASE MODEL; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHENOTYPE; PHOSPHORYLATION;

ANIMALS; DISEASE MODELS, ANIMAL; GLUTATHIONE; HUMANS; ISOTHIOCYANATES; KERATIN-16; KERATODERMA, PALMOPLANTAR; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PACHYONYCHIA CONGENITA; PHENOTYPE; PHOSPHORYLATION; RNA, MESSENGER;

EID: 84974573518     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI84870     Document Type: Article

References (49)

1. Coulombe PA, Hutton ME, Vassar R, Fuchs E. A function for keratins and a common thread among different types of epidermolysis bullosa simplex diseases. J Cell Biol. 1991;115(6):1661-1674.
2. Omary MB, Coulombe PA, McLean WH. Intermediate filament proteins and their associated diseases. N Engl J Med. 2004;351(20):2087-2100.
3. Szeverenyi I, et al. The Human Intermediate Filament Database: comprehensive information on a gene family involved in many human diseases. Hum Mutat. 2008;29(3):351-360.
4. Coulombe PA, Kerns ML, Fuchs E. Epidermolysis bullosa simplex: a paradigm for disorders of tissue fragility. J Clin Invest. 2009;119(7):1784-1793.
5. Pan X, Hobbs RP, Coulombe PA. The expanding significance of keratin intermediate filaments in normal and diseased epithelia. Curr Opin Cell Biol. 2013;25(1):47-56.
6. Hamada T, et al. How do keratinizing disorders and blistering disorders overlap? Exp Dermatol. 2013;22(2):83-87.
7. Smith FJ, et al. The genetic basis of pachyonychia congenita. J Invest Dermatol Symp Proc. 2005;10(1):21-30.
8. McLean WH, et al. Keratin 16 and keratin 17 mutations cause pachyonychia congenita. Nat Genet. 1995;9(3):273-278.
9. McGowan K, Coulombe PA. The wound repair-associated keratins 6, 16, and 17. Subcell Biochem. 1998;31:173-204.
10. Eliason MJ, Leachman SA, Feng BJ, Schwartz ME, Hansen CD. A review of the clinical phenotype of 254 patients with genetically confirmed pachyonychia congenita. J Am Acad Dermatol. 2012;67(4):680-686.
11. Lessard JC, et al. Keratin 16 regulates innate immunity in response to epidermal barrier breach. Proc Natl Acad Sci U S A. 2013;110(48):19537-19542.
12. Shah S, Boen M, Kenner-Bell B, Schwartz M, Rademaker A, Paller AS. Pachyonychia congenita in pediatric patients: natural history, features, and impact. JAMA Dermatol. 2014;150(2):146-153.
13. Lessard JC, Coulombe PA. Keratin 16-null mice develop palmoplantar keratoderma, a hallmark feature of pachyonychia congenita and related disorders. J Invest Dermatol. 2012;132(5):1384-1391.
14. Lushchak VI. Glutathione homeostasis and functions: potential targets for medical interventions. J Amino Acids. 2012;2012:736837.
15. Pastore A, et al. Determination of blood total, reduced, and oxidized glutathione in pediatric subjects. Clin Chem. 2001;47(8):1467-1469.
16. Dalton TP, Dieter MZ, Yang Y, Shertzer HG, Nebert DW. Knockout of the mouse glutamate cysteine ligase catalytic subunit (Gclc) gene: embryonic lethal when homozygous, and proposed model for moderate glutathione deficiency when heterozygous. Biochem Biophys Res Commun. 2000;279(2):324-329.
17. Yang Y, Dieter MZ, Chen Y, Shertzer HG, Nebert DW, Dalton TP. Initial characterization of the glutamate-cysteine ligase modifier subunit Gclm(-/-) knockout mouse. J Biol Chem. 2002;277(51):49446-49452.
18. Couto N, Malys N, Gaskell SJ, Barber J. Partition and turnover of glutathione reductase from Saccharomyces cerevisiae: a proteomic approach. J Proteome Res. 2013;12(6):2885-2894.
19. Kerns M, DePianto D, Yamamoto M, Coulombe PA. Differential modulation of keratin expression by sulforaphane occurs via Nrf2-dependent and -independent pathways in skin epithelia. Mol Biol Cell. 2010;21(23):4068-4075.
20. Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12(12):931-947.
21. Endo H, Sugioka Y, Nakagi Y, Saijo Y, Yoshida T. A novel role of the NRF2 transcription factor in the regulation of arsenite-mediated keratin 16 gene expression in human keratinocytes. Environ Health Perspect. 2008;116(7):873-879.
22. Alam J, Cook JL. Transcriptional regulation of the heme oxygenase-1 gene via the stress response element pathway. Curr Pharm Des. 2003;9(30):2499-2511.
23. Kwak MK, Itoh K, Yamamoto M, Sutter TR, Kensler TW. Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1, 2-dimethiole-3-thione. Mol Med. 2001;7(2):135-145.
24. Itoh K, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999;13(1):76-86.
25. Niture SK, Jain AK, Jaiswal AK. Antioxidant-induced modification of INrf2 cysteine 151 and PKC-delta-mediated phosphorylation of Nrf2 serine 40 are both required for stabilization and nuclear translocation of Nrf2 and increased drug resistance. J Cell Sci. 2009;122(pt 24):4452-4464.
26. Adams DR, Ron D, Kiely PA. RACK1, A multifaceted scaffolding protein: structure and function. Cell Commun Signal. 2011;9:22.
27. Kroger C, Loschke F, Schwarz N, Windoffer R, Leube RE, Magin TM. Keratins control intercellular adhesion involving PKC-α-mediated desmoplakin phosphorylation. J Cell Biol. 2013;201(5):681-692.
28. Kim YH, Coon A, Baker AF, Powis G. Antitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase. Cancer Chemother Pharmacol. 2011;68(2):405-413.
29. Oshimori N, Oristian D, Fuchs E. TGF-β promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell. 2015;160(5):963-976.
30. Hermanto U, Zong CS, Li W, Wang LH. RACK1, an insulin-like growth factor I (IGF-I) receptor-interacting protein, modulates IGF-I-dependent integrin signaling and promotes cell spreading and contact with extracellular matrix. Mol Cell Biol. 2002;22(7):2345-2365.
31. Jia D, et al. Up-regulation of RACK1 by TGF-β1 promotes hepatic fibrosis in mice. PLoS One. 2013;8(3):e60115.
32. Zhang Y, Talalay P, Cho CG, Posner GH. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci U S A. 1992;89(6):2399-2403.
33. Braun S, et al. Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Mol Cell Biol. 2002;22(15):5492-5505.
34. Schafer M, Dutsch S, auf dem Keller U, Werner S. Nrf2: a central regulator of UV protection in the epidermis. Cell Cycle. 2010;9(15):2917-2918.
35. Choi Y, Fuchs E. TGF-β and retinoic acid: regulators of growth and modifiers of differentiation in human epidermal cells. Cell Regul. 1990;1(11):791-809.
36. Chung BM, Arutyunov A, Ilagan E, Yao N, Wills-Karp M, Coulombe PA. Regulation of C-X-C chemokine gene expression by keratin 17 and hnRNP K in skin tumor keratinocytes. J Cell Biol. 2015;208(5):613-627.
37. Goldberg I, Fruchter D, Meilick A, Schwartz ME, Sprecher E. Best treatment practices for pachyonychia congenita. J Eur Acad Dermatol Venereol. 2014;28(3):279-285.
38. Leachman SA, et al. First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther. 2010;18(2):442-446.
39. Milstone LM, et al. Treatment of pachyonychia congenita. J Investig Dermatol Symp Proc. 2005;10(1):18-20.
40. Trochet D, Prudhon B, Vassilopoulos S, Bitoun M. Therapy for dominant inherited diseases by allele-specific RNA interference: successes and pitfalls. Curr Gene Ther. 2015;15(5):503-510.
41. Kerns ML, DePianto D, Dinkova-Kostova AT, Talalay P, Coulombe PA. Reprogramming of keratin biosynthesis by sulforaphane restores skin integrity in epidermolysis bullosa simplex. Proc Natl Acad Sci U S A. 2007;104(36):14460-14465.
42. Dinkova-Kostova AT, et al. Protection against UV-light-induced skin carcinogenesis in SKH-1 high-risk mice by sulforaphane-containing broccoli sprout extracts. Cancer Lett. 2006;240(2):243-252.
43. Dinkova-Kostova AT, et al. Induction of the phase 2 response in mouse and human skin by sulforaphane-containing broccoli sprout extracts. Cancer Epidemiol Biomarkers Prev. 2007;16(4):847-851.
44. MacGarvey NC, Suliman HB, Bartz RR, Fu P, Withers CM, KE Piantadosi CA. Activation of mitochondrial biogenesis by heme-oxygenase-1-mediated NF-E2-related factor-2 induction rescues mice from lethal Staphylococcus aureus sepsis. Am J Respir Crit Care Med. 2012;185(8):851-861.
45. Tufekci KU, Civi Bayin E, Genc S, Genc K. The Nrf2/ARE pathway: a promising target to counteract mitochondrial dysfunction in Parkinson's disease. Parkinsons Dis. 2011;2011:314082.
46. Bernot KM, Coulombe PA, McGowan KM. Keratin 16 expression defines a subset of epithelial cells during skin morphogenesis and the hair cycle. J Invest Dermatol. 2002;119(5):1137-1149.
47. Strickland JE, et al. Development of murine epidermal cell lines which contain an activated rasHa oncogene and form papillomas in skin grafts on athymic nude mouse hosts. Cancer Res. 1988;48(1):165-169.
48. Seegmiller BL. Gene expression profiling in pachyonychia congenita skin. J Dermatol Sci. 2015;77(3):156-165.
49. Hobbs RP, et al. Keratin-dependent regulation of Aire and gene expression in skin tumor keratinocytes. Nat Genet. 2015;47(8):933-938.